- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00110305
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
11 de junho de 2014 atualizado por: Tibotec Pharmaceuticals, Ireland
A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
Visão geral do estudo
Status
Concluído
Condições
Descrição detalhada
This is a randomized (the study medication is assigned by chance), active controlled (participants are assigned to either a recognized effective treatment or the study medication) study.
This study consists of 3 phases: screening phase (4 weeks), treatment phase (96 weeks), and follow up phase (4 weeks).
In the treatment phase, participants will be randomly assigned to 1 of the 4 treatment groups: (1) TMC278 25 mg, (2) TMC278 75 mg, (3) TMC278 150 mg, or (4) efavirnez (control group); along with investigator selected 2 non-nucleoside reverse transcriptase inhibitor (NRTIs) until Week 96.
TMC278 will be assigned by double-blinded fashion (participant and investigator are not aware of the TMC278 dose what participants will receive) and efavirnez will be assigned by open-label fashion (all people know what treatment participants will receive).
After Week 96, 3 optional open-label (all people know the identity of the intervention) extension periods will be conducted to collect long term safety and effectiveness data of TMC278.
3 optional extension periods are: first optional extension period (all participants will receive TMC278 75 mg + 2 NRTIs from Week 96 to Week144); second optional extension period (all participants will receive TMC278 25 mg + 2 NRTIs from Week 144 to Week 240); and third optional extension period (all participants will receive TMC278 25 mg + 2 NRTIs from Week 240 until TMC278 is commercially available).
Participants on efavirenz group will have the option to continue on efavirenz + 2 NRTIs until the total treatment duration of 240 weeks.
Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, physical examination, and vital signs which will be monitored throughout the study.
The maximum duration of the study will be 104, 152, or 248 weeks, plus the optional third extension period.
Tipo de estudo
Intervencional
Inscrição (Real)
368
Estágio
- Fase 2
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Berlin, Alemanha
-
Freiburg, Alemanha
-
Köln, Alemanha
-
München, Alemanha
-
-
-
-
-
Buenos Aires, Argentina
-
Rosario, Argentina
-
-
-
-
-
Campinas, Brasil
-
Curitiba, Brasil
-
Pinheiros, Brasil
-
Rio De Janeiro, Brasil
-
Sao Paulo, Brasil
-
-
-
-
-
Beijing, China
-
-
-
-
California
-
Beverly Hills, California, Estados Unidos
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos
-
-
Florida
-
Orlando, Florida, Estados Unidos
-
Tampa, Florida, Estados Unidos
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos
-
-
New York
-
Stony Brook, New York, Estados Unidos
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos
-
-
Texas
-
Addison, Texas, Estados Unidos
-
-
Washington
-
Seattle, Washington, Estados Unidos
-
-
-
-
-
Kazan, Federação Russa
-
Moscow, Federação Russa
-
Moscow N/A, Federação Russa
-
Nizhny Novgorod, Federação Russa
-
Saint-Petersburg, Federação Russa
-
St Petersburg, Federação Russa
-
Volgograd, Federação Russa
-
-
-
-
-
Paris, França
-
Paris Cedex 10, França
-
Paris Cedex 12, França
-
Tourcoing, França
-
-
-
-
-
Ciudad De Mexico, México
-
-
-
-
-
San Juan, Porto Rico
-
-
-
-
-
London, Reino Unido
-
Manchester, Reino Unido
-
-
-
-
-
Bangkok, Tailândia
-
Chiang Mai, Tailândia
-
Khon Kaen, Tailândia
-
-
-
-
-
Kampala, Uganda
-
-
-
-
-
Bloemfontein, África do Sul
-
Cape Town, África do Sul
-
Johannesburg, África do Sul
-
-
-
-
-
Wien, Áustria
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Documented human immunodeficiency virus type 1 (HIV-1) infection
- Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or equal to 2 weeks treatment prior to screening with an nucleoside reverse transcriptase inhibitors
- HIV-1 plasma viral load above 5000 HIV-1 RNA copies per milliliter, at screening
- Cortisol of at least 550 nano moles per liter (19.9 microgram per deciliter) at screening
- Sensitivity to investigator selected nucleosides, at screening
Exclusion Criteria:
- Currently having active Acquired Immunodeficiency Syndrome (AIDS) defining illness
- Known or suspected acute (primary) HIV-1 infection
- Any current or history of adrenal disorder, and an acute hepatitis A, B, or C infection
- Documented genotypic evidence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance at screening
- Pregnant or breastfeeding females
- Not agree to protocol-defined effective use of contraception
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: TMC278 25 mg
Participants will receive TMC278 25 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
TMC278 25 mg tablet will be administered once daily.
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Outros nomes:
|
|
Experimental: TMC278 75 mg
Participants will receive TMC278 75 mg once daily up to Week 144.
Later on, participants will receive TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Outros nomes:
TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
|
|
Experimental: TMC278 150 mg
Participants will receive TMC278 150 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Outros nomes:
TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
|
|
Comparador Ativo: Efavirenz
Participants will receive efavirenz 600 mg once daily up to Week 96.
Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Outros nomes:
Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Prazo: Week 48
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 48
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Prazo: Week 96
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
Prazo: Week 96
|
The analysis is based on the last observed viral load data within the Week 96 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Prazo: Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
Prazo: Week 240
|
The analysis is based on the last observed viral load data within the Week 240 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 400 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Prazo: Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 96
Prazo: Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 96
Prazo: Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 240
Prazo: Baseline (Day 1 of Week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 240
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 240
Prazo: Baseline (Day 1 of week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of week 0) to Week 240
|
|
Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
Prazo: Week 240
|
Virologic failure for the resistance determinations was defined as a viral load greater than 0.5 log10 copies /mL above the nadir with a minimum of 500 copies/mL.
For this study, treatment-emergent mutations (for at least one treatment) are presented as Resistance associated mutation (RAMs): i) Non-nucleotide reverse transcriptase inhibitor (NNRTI) RAMs, ii) Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).
|
Week 240
|
|
Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) for TMC278
Prazo: Up to Week 96
|
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Trough Plasma Concentration (Ctrough) for TMC278
Prazo: Up to Week 96
|
For each participant, a single value for trough (i.e.
predose) plasma concentration (Ctrough) of TMC278 was estimated from a population pharmacokinetic model, based on samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Number of Participants With Virologic Response (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm, by Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) Quartiles
Prazo: Up to Week 96
|
Quartile 1, 2, 3 and 4 of AUC24h means the quartile with the lowest 25%, 26-50%, 51-75% and the highest 25% of AUC24h values, respectively, irrespective of the different doses of TMC278.
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
Virologic response was calculated by time to loss of virologic response (TLOVR) algorithm.
|
Up to Week 96
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de junho de 2005
Conclusão Primária (Real)
1 de dezembro de 2011
Conclusão do estudo (Real)
1 de dezembro de 2011
Datas de inscrição no estudo
Enviado pela primeira vez
5 de maio de 2005
Enviado pela primeira vez que atendeu aos critérios de CQ
5 de maio de 2005
Primeira postagem (Estimativa)
6 de maio de 2005
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
25 de junho de 2014
Última atualização enviada que atendeu aos critérios de controle de qualidade
11 de junho de 2014
Última verificação
1 de junho de 2014
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Doenças do sistema imunológico
- Doenças de Vírus Lento
- Infecções por HIV
- Síndrome da Imunodeficiência Adquirida
- Síndromes de Deficiência Imunológica
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Agentes anti-HIV
- Antirretrovirais
- Inibidores da enzima citocromo P-450
- Indutores Enzimáticos do Citocromo P-450
- Indutores de citocromo P-450 CYP3A
- Indutores do Citocromo P-450 CYP2B6
- Inibidores do citocromo P-450 CYP2C9
- Inibidores do citocromo P-450 CYP2C19
- Inibidores da transcriptase reversa
- Efavirenz
- Rilpivirina
Outros números de identificação do estudo
- CR006760
- TMC278-C204 (Outro identificador: Tibotec Pharmaceuticals, Ireland)
- R278474-C204 (Outro identificador: Tibotec Pharmaceuticals, Ireland)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .